AI Summary
This article discusses the results of an NCI trial indicating that administering pembrolizumab to patients after surgery for high-risk muscle invasive bladder cancer can double the median length of time they remain cancer-free compared to observation alone after surgery. This finding underscores the potential benefits of immunotherapy in treating high-risk bladder cancer patients.
An NCI trial shows that giving patients pembrolizumab after surgery for high-risk muscle invasive bladder cancer doubles the median length of time that they remain cancer free, compared with observation alone after surgery.